Scientists from the Helmholtz Zentrum Munchen, Germany have found that these extracts represent a potential new class of anti-HIV-1 agents for the treatment of AIDS.
Researchers demonstrate that root extracts of the medicinal plant Pelargonium sidoides (PS) contain compounds that attack HIV-1 particles and prevent virus replication.
A team spearheaded by Dr Markus Helfer and Professor Ruth Brack-Werner performed a detailed investigation of the effects of PS extracts on HIV-1 infection of cultured cells.
PS extracts block attachment of virus particles to host cells and thus effectively prevent the virus from invading cells.
Chemical analyses revealed that the antiviral effect of the PS extracts is mediated by polyphenols. Polyphenol mixtures isolated from PS extracts retain high anti-HIV-1 activity but are even less toxic for cells than the crude extract.
Safety of PS-extracts has been established in several clinical trials, researchers said.
"PS-extracts are a very promising lead for the development of the first scientifically validated phytomedicine against HIV-1. PS extracts attack HIV-1 with a mode-of-action that is different from all anti-HIV-1 drugs in clinical use," research group leader Brack-Werner said.
"The results of our study and the proven safety of PS extracts encourages their testing in HIV-1 infected individuals as next step," said Brack-Werner.
According to the World Health Organisation (WHO), more than 35 million people in the world are infected with HIV, the majority with HIV-1, researchers said.
Without treatment, HIV destroys the immune system and causes the acquired immunodeficiency syndrome (AIDS), which is a life-threatening disease. HIV/AIDS is one of the 10 leading causes of death worldwide, they said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
